Abstract Number: 2339 • 2019 ACR/ARP Annual Meeting
Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is an extra-articular manifestation with a poor prognosis. In clinical practice, to establish such a diagnosis requires…Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting
Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…Abstract Number: 2341 • 2019 ACR/ARP Annual Meeting
Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA) lead to significant morbidity and mortality. Lung manifestations in RA are myriad, however little is known about how…Abstract Number: 2342 • 2019 ACR/ARP Annual Meeting
Association of Serum KL-6 Level and Change of Pulmonary Function in Interstitial Lung Disease of Rheumatoid Arthritis – Data from Prospective KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) Study
Background/Purpose: Interstitial lung disease (ILD) is the most common lung disease among rheumatoid arthritis (RA) patients. Although the overall mortality rates for RA have decreased…Abstract Number: 2343 • 2019 ACR/ARP Annual Meeting
Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease
Background/Purpose: Pulmonary complication is one of the leading causes of mortality in patients with rheumatoid arthritis (RA). Pre-existing lung disease is known as a risk…Abstract Number: 2344 • 2019 ACR/ARP Annual Meeting
Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) as an extra-articular manifestation of rheumatoid arthritis (RA) leads to significant morbidity and mortality. As data is limited, this study…Abstract Number: 2345 • 2019 ACR/ARP Annual Meeting
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA).Interstitial lung disease (ILD) associated with Rheumatoid Arthritis (RA) has a poor…Abstract Number: 2346 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors
Background/Purpose: A wide spectrum of interstitial lung abnormalities (ILA) occurs in patients with rheumatoid arthritis (RA). This study characterized ILA in large single-center cohort, including…Abstract Number: 2347 • 2019 ACR/ARP Annual Meeting
Long-term Survival in Lung Transplantation and Allograft Rejection in Patients with Interstitial Lung Disease Related with Rheumatoid Arthritis: Study from a Single Referral Center
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with rheumatoid arthritis (RA). In end-stage RA-ILD, lung transplant becomes the only…Abstract Number: 2348 • 2019 ACR/ARP Annual Meeting
KL-6 Is a Useful Marker to Monitor the Progression of RA-ILD, but Not to Diagnose or Predict the Development of ILD
Background/Purpose: Interstitial lung disease (ILD) is a critical comorbidity in RA. To manage RA-ILD, early diagnosis and monitoring disease progression are important. KL-6 is a marker…Abstract Number: 2349 • 2019 ACR/ARP Annual Meeting
Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review
Background/Purpose: Interstitial lung disease (ILD) is the most common lung manifestation of RA and the 2nd leading cause of death in RA patients.1,2 The purpose…Abstract Number: 2350 • 2019 ACR/ARP Annual Meeting
Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) patients are at elevated risk for cardiovascular (CV) events, but efficient risk stratification based on CV prediction models is not part…Abstract Number: 2351 • 2019 ACR/ARP Annual Meeting
Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
Background/Purpose: The EXTEND open-label extension study (NCT01146652) is collecting data on long-term treatment of RA with sarilumab as monotherapy and in combination with conventional synthetic…Abstract Number: 2352 • 2019 ACR/ARP Annual Meeting
Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis
Background/Purpose: Distinct subgroups of RA are being identified by clinical, biochemical, and genomic markers. ACPA positivity is one such biomarker associated with a clinical profile…Abstract Number: 2353 • 2019 ACR/ARP Annual Meeting
ACPA Testing and Resultant Treatment Patterns in Patients with Rheumatoid Arthritis: Findings from US Community Rheumatology Practices
Background/Purpose: Research is redefining RA as a heterogeneous group of diseases distinguished by clinical, biochemical, and genomic markers. ACPA positivity is one such biomarker associated…
ACR Meeting Abstracts